About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Diffusion-weighted Imaging Study in Cancer of the Ovary

NCT01505829·6 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Institute of Cancer Research, United Kingdom

With

Cancer Research UK
Royal Marsden NHS Foundation Trust
Cambridge University Hospitals NHS Foundation Trust
Imperial College Healthcare NHS Trust
Northumbria Healthcare NHS Foundation Trust
East and North Hertfordshire NHS Trust

Age

18–80

Sex

FEMALE

Healthy volunteers

Accepted

You may be eligible if

Histologically confirmed ovarian, primary peritoneal or fallopian tube cancer stage III or IV
Scheduled to receive neoadjuvant chemotherapy (carboplatin/cisplatin)with planned debulking surgery.

You may not be if

Life expectancy of less than 6 months
MRI contraindications
Low grade or heavily calcified disease

The record

StatusCompleted

PhaseNo phase

Taking part134

StartedAug 2012

UpdatedJan 23, 2020

Conditions

Ovarian Cancer Peritoneal Metastases

Where6

Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Queen Elizabeth Hospital
Newcastle, Gateshead, United Kingdom
Mount Vernon Cancer Centre
Northwood, Middlesex, United Kingdom

Clareo Health | Diffusion-weighted Imaging Study in Cancer of the Ovary